References
- Bakheit AH, Abd-Elgalil AA, Mustafa B, et al. Telmisartan. Profiles Drug Subst Excip Relat Methodol. 2015;40:371–429.
- Deppe S, Boger RH, Weiss J, et al. Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties. Expert Opin Drug Metab Toxicol. 2010;6(7):863–871.
- White WB. Comparative effects of telmisartan in the treatment of hypertension. J Clin Hypertens. 2000;5(4):20–25.
- Badan Pengawas Obat dan Makanan Republik Indonesia (BPOM). Pedoman Uji Bioekivalensi. Jakarta: Badan POM; 2015.
- College ter Beoordeling van Geneesmiddelen (CBG). Public assessment report of the medicines evaluation board in the Netherlands: Telmisartan Torrent 20 mg, 40 mg, 80 mg tablets Torrent Pharma GmbH, Germany. Netherlands: Medicines Evaluation Board; 2012 (report number: RVG 110355–110357).
- Chow SC. Bioavailability and bioequivalence in drug development. Wiley Interdiscip Rev Comput Stat. 2014;6(4):304–312.
- Committee for Medicinal Products for Human Use (CHMP). Guideline on the investigation of bioequivalence. London: European Medicines Agency; 2010 (Doc. Ref.: CPMP/EWP/QWP/1401/98 Rev. 1/Corr*).
- Haidar SH, Makhlouf F, Schuirmann DJ, et al. Evaluation of a scaling approach for the bioequivalence of highly variable drugs. AAPS J. 2008;10(3):450–454.
- Dragojevic-Simic V, Kovacevic A, Jacevic V, et al. Bioequivalence study of two formulations of itraconazole 100 mg capsules in healthy volunteers under fed conditions: a randomized, three-period, reference-replicated, crossover study. Expert Opin Drug Metab Toxicol. 2018;14(9):979–988.
- Kang WY, Seong SJ, Ohk B, et al. Pharmacokinetic and bioequivalence study of a telmisartan/S-amlodipine fixed-dose combination (CKD-828) formulation and coadministered telmisartan and S-amlodipine in healthy subjects. Drug Des Devel Ther. 2018;12:545–553.
- Oh M, Park SE, Ghim JL, et al. Comparative pharmacokinetics of a fixed-dose combination vs concomitant administration of telmisartan and S-amlodipine in healthy adult volunteers. Drug Des Devel Ther. 2017;11:3543–3550.
- Chae DW, Son M, Kim Y, et al. Pharmacokinetics of a telmisartan/rosuvastatin fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjects. Int J Clin Pharmacol Ther. 2015;53(10):883–889.
- Tothfalusi L, Endrenyi L. Sample sizes for designing bioequivalence studies for highly variable drugs. J Pharm Pharm Sci. 2012;15(1):73–84.
- Food and Drug Administration (FDA). Draft guidance on Telmisartan; 2010; [cited 2019 Jan 2]. Available from: https://www.google.com/url?sa=t&source=web&rct=j&url=https://www.accessdata.fda.gov/drugsatfda_docs/psg/Telmisartan_tabs_20850_RC5-08.pdf&ved=2ahUKEwi1zpe99K3pAhVLfSsKHVj0DzIQFjAAegQIARAB&usg=AOvVaw2N4RKBK1szl0vmq5NN8ZqR
- Shen J, Jiao Z, Li ZD, et al. HPLC determination of telmisartan in human plasma and its application to a pharmacokinetic study. Pharmazie. 2005;60(6):418–420.
- Zhang H, Jiang Y, Wen J, et al. Rapid determination of telmisartan in human plasma by HPLC using a monolithic column with fluorescence detection and its application to a bioequivalence study. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877(29):3729–3733.
- Committee for Human Medicinal Products (CHMP). Questions & Answers: positions on specific questions addressed to the Pharmacokinetics Working Party (PKWP). London: European Medicines Agency; 2015 (EMA/618604/2008 Rev. 13).
- Committee for Medicinal Products for Human Use (CHMP). Guideline on bioanalytical method validation. London: European Medicines Agency; 2011 (EMEA/CHMP/EWP/192217/2009 Rev. 1 Corr. 2**).
- Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens. 2000;14(S1):S73–S86.
- Food and Drug Administration (FDA). Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products- general consideration. USA: Department of Health and Human Services; 2003.